m＋Medelevator.RU
← Поиск публикаций
British journal of cancer · 1992

A phase II study of high dose epirubicin in unresectable non small cell lung cancer.

Название и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Smit EF, Berendsen HH, Piers DA, Smeets J, Riva A, Postmus PE

Аннотация

Epirubicin (EPI), a doxorubicin analogue, is reported to have equal antitumour activity with lower cardiac and systemic toxicity. Recently, the maximum tolerated dose of this drug has been revised upwards with reported increased response rates in several malignancies. We initiated a phase II study of high-dose EPI as initial treatment for patients with advanced non-small cell lung cancer (NSCLC) (stage III and IV). Between May 1988 and November 1989, 25 patients were entered. The starting dose of EPI was 135 mg m-2, with dose attenuations and escalations of 15 mg m-2 based on mid-cycle evaluation of toxicity. Treatment was repeated every 3 weeks. Nine partial responses (36%, 95% CI: 18-57.5%) and 11 patients with disease stabilisation (44%) were observed. Median (range) time to progression was 19 (3-70) weeks. Median (range) survival is 32 (9-116+) weeks. There were no treatment related deaths. Major side effects were leukocytopenia WHO grade III/IV (23% of courses) and mucositis WHO grade II/III (15% of courses). In two patients left ventricular ejection fraction decreased greater than 15% compared to baseline values after a cumulative Epirubicin dose of 435 mg m-2, and therefore went off study. In none of the patients clinical signs of congestive heart failure were observed. We conclude from our data that high-dose EPI, contrary to previous negative studies using lower doses of EPI, ranks amongst the most active regimens against advanced NSCLC. Toxicity of high-dose EPI is moderate. Further evaluation of this compound in combination regimens is recommended.

Перевод полного текста: Перевод в очереди

Читать найденный полный текст

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/ .

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Case D. C., Jr, Ervin T. J., Gams R., Sonneborn H. L., Paul S. D., Oldham F. B. Phase I-II study of epirubicin in multiple myeloma. Cancer Res. 1988 Nov 1;48(21):6246–6248.

Case D. C., Jr, Gams R., Ervin T. J., Boyd M. A., Oldham F. B. Phase I-II trial of high-dose epirubicin in patients with lymphoma. Cancer Res. 1987 Dec 1;47(23):6393–6396.

Cersosimo R. J., Hong W. K. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol. 1986 Mar;4(3):425–439. doi: 10.1200/JCO.1986.4.3.425.

Cortes E. P., Holland J. F., Glidewell O. Amputation and adriamycin in primary osteosarcoma: a 5-year report. Cancer Treat Rep. 1978 Feb;62(2):271–277.

Ferrazzi E., Nicoletto O., Vinante O., Pagnin P., Maraglino G., Ganzina F., Fiorentino M. V. Phase II study of 4'epi-doxorubicin. Tumori. 1982 Oct 31;68(5):431–435. doi: 10.1177/030089168206800513.

Frei E., 3rd, Canellos G. P. Dose: a critical factor in cancer chemotherapy. Am J Med. 1980 Oct;69(4):585–594. doi: 10.1016/0002-9343(80)90472-6.

Jones R. B., Holland J. F., Bhardwaj S., Norton L., Wilfinger C., Strashun A. A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Oncol. 1987 Feb;5(2):172–177. doi: 10.1200/JCO.1987.5.2.172.

Luedke D. W., Einhorn L., Omura G. A., Sarma P. R., Bartolucci A. A., Birch R., Greco F. A. Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial. J Clin Oncol. 1990 May;8(5):886–891. doi: 10.1200/JCO.1990.8.5.886.

Nielsen D., Jensen J. B., Dombernowsky P., Munck O., Fogh J., Brynjolf I., Havsteen H., Hansen M. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol. 1990 Nov;8(11):1806–1810. doi: 10.1200/JCO.1990.8.11.1806.

Preisler H. D., Gessner T., Azarnia N., Bolanowska W., Epstein J., Early A. P., D'Arrigo P., Vogler R., Winton L., Chervenik P. Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia. Cancer Chemother Pharmacol. 1984;12(2):125–130. doi: 10.1007/BF00254604.

Rapp E., Pater J. L., Willan A., Cormier Y., Murray N., Evans W. K., Hodson D. I., Clark D. A., Feld R., Arnold A. M. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. J Clin Oncol. 1988 Apr;6(4):633–641. doi: 10.1200/JCO.1988.6.4.633.

Razek A., Valeriote F., Vietti T. Survival of hematopoietic and leukemic colony-forming cells in vivo following the administration of daunorubicin or adriamycin. Cancer Res. 1972 Jul;32(7):1496–1500.

Rozencweig M., ten Bokkel Huinink W., Cavalli F., Bruntsch U., Dombernowsky P., Høst H., Bramwell V., Renard G., Van Glabbeke M., Decoster G. Randomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancer. J Clin Oncol. 1984 Apr;2(4):275–281. doi: 10.1200/JCO.1984.2.4.275.

Tjuljandin S. A., Doig R. G., Sobol M. M., Watson D. M., Sheridan W. P., Morstyn G., Mihaly G., Green M. D. Pharmacokinetics and toxicity of two schedules of high dose epirubicin. Cancer Res. 1990 Aug 15;50(16):5095–5101.

Torti F. M., Bristow M. M., Lum B. L., Carter S. K., Howes A. E., Aston D. A., Brown B. W., Jr, Hannigan J. F., Jr, Meyers F. J., Mitchell E. P. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res. 1986 Jul;46(7):3722–3727.

Wheeler R. H., Ensminger W. D., Thrall J. H., Anderson J. L. High-dose doxorubicin: an exploration of the dose-response curve in human neoplasia. Cancer Treat Rep. 1982 Mar;66(3):493–498.

Wils J. A. Phase II trial of 4'-epi-doxorubicin in metastatic colorectal carcinoma. Invest New Drugs. 1984;2(4):397–399. doi: 10.1007/BF00171592.

Woods R. L., Williams C. J., Levi J., Page J., Bell D., Byrne M., Kerestes Z. L. A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer. 1990 Apr;61(4):608–611. doi: 10.1038/bjc.1990.135.